Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 3/20 | 0.61 |
| ▸ | EGFR | P00533 | 15/20 | 0.59 |
| ▸ | AURKA | O14965 | 2/20 | 0.56 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.56 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.53 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.47 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | INSR | P06213 | 1/20 | 0.47 |
| ▸ | FBP1 | P09467 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | FLT4 | P35916 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | CLK1 | P49759 | 1/20 | 0.47 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.47 |
| ▸ | TEK | Q02763 | 1/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9901154 | 0.91 | EGFR (0.55) | DYRK1AEGFRAURKARPS6KB1ERBB2 | |
| SCHEMBL14733429 | 0.76 | DYRK1A (1.00) | DYRK1AEGFRERBB2 | |
| SCHEMBL17060609 | 0.76 | DYRK1A (1.00) | DYRK1AEGFRERBB2 | |
| SCHEMBL27686240 | 0.75 | EGFR (0.63) | EGFRAURKARPS6KB1ERBB2GRM1 | |
| SCHEMBL7120632 | 0.75 | EGFR (0.76) | DYRK1AEGFRAURKARPS6KB1ERBB2 | |
| SCHEMBL6129182 | 0.74 | EGFR (0.75) | EGFRAURKAERBB2ERBB4INSR | |
| SCHEMBL23950086 | 0.74 | EGFR (0.66) | DYRK1AEGFRAURKAERBB2GRM1 | |
| SCHEMBL2714067 | 0.73 | AURKA (0.57) | DYRK1AEGFRAURKARPS6KB1ERBB2 | |
| Water SCHEMBL28549001 | 0.73 | EGFR (0.74) | EGFRAURKAERBB2ERBB4INSR | |
| SCHEMBL27860183 | 0.73 | EGFR (0.63) | EGFRAURKARPS6KB1ERBB2GRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2648509-B1 | SUBSTITUTED 4-(ARYLAMINO) SELENOPHENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LTD (IN) | 2015-04-29 | — | — | EP | claimed |
| EP-2648509-A2 | SUBSTITUTED 4-(ARYLAMINO) SELENOPHENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | Kasina Laila Innova Pharmaceuticals Private Ltd. (IN) | 2013-10-16 | — | — | EP | claimed |
| WO-2012077135-A2 | SUBSTITUTED 4-(ARYLAMINO) SELENOPHENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITED (IN) | 2012-06-14 | — | — | WO | claimed |
| US-9090633-B2 | Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITED (IN) | 2015-07-28 | — | — | US | disclosed |
| EP-2648509-B1 | SUBSTITUTED 4-(ARYLAMINO) SELENOPHENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LTD (IN) | 2015-04-29 | — | — | EP | disclosed |
| US-20130287767-A1 | SUBSTITUTED 4-(ARYLAMINO) SELENOPHENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITED (IN) | 2013-10-31 | — | — | US | disclosed |
| EP-2648509-A2 | SUBSTITUTED 4-(ARYLAMINO) SELENOPHENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | Kasina Laila Innova Pharmaceuticals Private Ltd. (IN) | 2013-10-16 | — | — | EP | disclosed |
| WO-2012077135-A2 | SUBSTITUTED 4-(ARYLAMINO) SELENOPHENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITED (IN) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130287767-A1 | SUBSTITUTED 4-(ARYLAMINO) SELENOPHENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | SELENOI, VHL, DPYD | DYRK1A 2910/4885EGFR 443/4885AURKA 1612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.